The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis
Discover Oncology · 18.12.2024 · 15 (1)
DOI: 10.1007/s12672-024-01683-w ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Discover Oncology, online erschienen am 18.12.2024. Verfasst von Zhicong Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 33000…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: This study aimed to determine the prognostic survival impact of preoperative carbohydrate CA19-9 levels in resectable cholangiocarcinoma. METHODS: PubMed, Web of Science, Cochrane, and Embase databases were searched for articles published through April 28, 2023. The relationship between preoperative serum carbohydrate antigen 19-9 and the prognosis of patients with resectable cholangiocarcinoma was analyzed. Heterogeneity between studies was assessed by means of the I2 statistic. We also performed subgroup analyses based on anatomical site of the tumor, geographic region, time of occurrence, and different levels of CA19-9. A random effects model was performed to express effect sizes as Hazard Ratio (HR) with 95% confidence intervals (CIs). RESULTS: A total of 60 original studies were eligible for inclusion, with a total of 15,031 patients with all sites, including 9014 males. The overall Hazard Ratio for all studies was 1.90 (95% CI 1.74-2.07, p < 0.001, Z = 14.59). Publication bias was suggested by the Begg's test (p = 0.014 < 0.05), and the overall HR was 1.66 (95% CI 1.53-1.80, p < 0.001, Z = 12.027) after the trim-and-filling method. Subgroup analyses showed that intrahepatic cholangiocarcinoma (HR = 2.00, 95% CI 1.79-2.23), extrahepatic cholangiocarcinoma (HR = 1.65, 95% CI 1.49-1.82), hilar cholangiocarcinoma (HR = 1. 82, 95% CI 1.60-2.07), and distal cholangiocarcinoma (HR = 1.66, 95% CI 1.27-2.15) were predicted to be linked with prognosis. Elevated CA19-9 levels were associated with an increased risk of death. CONCLUSIONS: This meta-analysis showed that elevated CA19-9 levels were correlated with a poor prognosis in cholangiocarcinoma. In future, more distal and hilar cholangiocarcinoma should be included in statistical studies to improve the accuracy of our conclusions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China.
- Department of General Surgery, Yellow River Sanmenxia Hospital, Sanmenxia, 472000, China.
- The First People's Hospital of Xiushui County, Jiujiang, 332400, China.
- Medical School, Hunan University of Chinese Medicine, Changsha, 410208, China.
- Department of Hepatobiliary Surgery, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330006, China. chen720806@163.com.
Zitieren
APA
Wang, Z., Shi, Y., Xiong, G., Han, M., & Chen, X. (2024). The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-024-01683-w
Vancouver
Wang Z, Shi Y, Xiong G, Han M, Chen X. The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis. Discover Oncology. 2024;15(1). doi:10.1007/s12672-024-01683-w
BibTeX
@article{Wang2024,
author = {Wang, Zhicong and Shi, Yabo and Xiong, Ganwei and Han, Mengxi and Chen, Xiaoliang},
title = {The prognostic impact of preoperative CA19-9 on resectable cholangiocarcinoma: a comprehensive systematic review and meta-analysis},
journal = {Discover Oncology},
year = {2024},
volume = {15},
number = {1},
doi = {10.1007/s12672-024-01683-w}
}
EUVIMED